Loading…
HUTCHMED (China) Limited is projected to rise to $11.24 by 2027, a +4% move from its current price of $10.77. HCM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $10.52 | $10.77 | $11.01 | -0.04% |
| Aug 2 | $10.42 | $10.76 | $11.12 | -0.08% |
| Aug 3 | $10.34 | $10.76 | $11.19 | -0.11% |
| Aug 4 | $10.27 | $10.75 | $11.26 | -0.15% |
| Aug 5 | $10.21 | $10.75 | $11.31 | -0.19% |
| Aug 6 | $10.16 | $10.75 | $11.36 | -0.23% |
| Aug 7 | $10.11 | $10.74 | $11.41 | -0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.11 | $10.74 | $11.41 | -0.27% |
| Week 2 | $9.84 | $10.71 | $11.67 | -0.53% |
| Week 3 | $9.62 | $10.68 | $11.86 | -0.80% |
| Week 4 | $9.44 | $10.66 | $12.02 | -1.07% |
| Week 5 | $9.28 | $10.63 | $12.16 | -1.33% |
| Week 6 | $9.14 | $10.60 | $12.29 | -1.59% |
| Week 7 | $9.01 | $10.57 | $12.40 | -1.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
HUTCHMED (China) Limited is a healthcare company that discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. Its portfolio includes Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutant AML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc.
The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HUTCHMED (China) Limited trades in the Healthcare sector. The stock is currently priced at $10.77 and carries a market capitalization of $1.87B, with a global rank of 1957. The current price is supported by a forecast path that shows modest upside in the near term and stronger upside longer term.
By 2030 the average price is projected to be $14.73 with a potential max of $20.68 and an ROI of 36.7, while by 2050 the average price could reach $52.30 with a max of $90.76 and an ROI of 385.6, reflecting a bullish longer‑term trajectory. The 2026 forecast holds an average price of $10.77, the same as the current price, with a min of $9.99 and a max of $13.42 and an ROI of 0, indicating a neutral near‑term stance.
A major floor 15.1% below — a decisive break under it would weaken the trend.
The nearest floor, 7.2% below — buyers have tended to step in here.
The nearest ceiling, 8.2% above — a clean break opens room to run.
A major ceiling 46.1% above — clearing it would confirm fresh momentum.
Key HCM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HCM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.10 | Sell | $11.07 | Sell |
| MA 10 | $11.09 | Sell | $11.10 | Sell |
| MA 20 | $11.19 | Sell | $11.10 | Sell |
| MA 50 | $11.06 | Sell | $11.43 | Sell |
| MA 100 | $12.59 | Sell | $12.22 | Sell |
| MA 200 | $13.59 | Sell | $13.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.04 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -146.99 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -4.27 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | 0.21 | Buy |
| Ultimate (7,14,28) | 40.00 | Neutral |
| Momentum (10) | -0.84 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 11.16 | Sell |
| ADX (14) | 13.19 | Neutral |
| ATR (14) | 0.23 | Info |
The near‑term picture is bearish. The RSI14 is 40, indicating cautious momentum. The stock trades below the 50‑day average of $11.06 and well below the 200‑day average of $13.59, suggesting limited upside in the immediate view.
It sits on a near‑term support of $9.99 and faces resistance at $11.65, with a 30‑day price range from $9.26 to $12.52. The volatility profile is elevated, with an annualized volatility of 40.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $10.77 | $13.42 | 0% | Neutral | |
| $9.10 | $11.24 | $14.60 | +4% | Neutral | |
| $9.54 | $12.07 | $16.19 | +12% | Neutral | |
| $9.39 | $12.10 | $16.64 | +12% | Neutral | |
| $11.23 | $14.73 | $20.68 | +37% | Bullish | |
| $12.71 | $16.91 | $24.20 | +57% | Bullish | |
| $12.21 | $16.48 | $23.97 | +53% | Bullish | |
| $12.63 | $17.27 | $25.51 | +60% | Bullish | |
| $12.94 | $17.92 | $26.84 | +66% | Bullish | |
| $13.30 | $18.63 | $28.27 | +73% | Bullish | |
| $17.52 | $25.89 | $41.48 | +140% | Bullish | |
| $32.34 | $52.30 | $90.76 | +386% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.99 | $10.77 | $12.55 | +0.00% |
| August 2026 | $9.07 | $10.60 | $12.66 | -1.55% |
| September 2026 | $8.83 | $10.40 | $12.56 | -1.90% |
| October 2026 | $8.98 | $10.64 | $12.96 | +2.27% |
| November 2026 | $9.16 | $10.90 | $13.38 | +2.48% |
| December 2026 | $9.09 | $10.86 | $13.42 | -0.36% |
Click any year to see its month-by-month HCM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HCM price prediction for 2026 points to an average of $10.77 (low $9.99, high $13.42) — a potential gain of 0% on today's $10.77. A consolidation phase looks the most probable path here.
In 2027, HCM is projected to trade between $9.10 and $14.60, averaging $11.24 — a potential gain of +4% from today's $10.77. That is up +4% on the projected 2026 average. Price action looks broadly range-bound.
HUTCHMED (China) Limited's 2028 outlook centres on $12.07, within a $9.54 to $16.19 range. That is up +7% on the projected 2027 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, HCM could reach as high as $16.64, with a base case around $12.10 and support toward $9.39 — roughly +12% from $10.77. Price action looks broadly range-bound.
Expect HCM to range from $11.23 to $20.68 through 2030. The $14.73 average target implies a +37% move from current prices. That is up +22% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The HCM price prediction for 2031 points to an average of $16.91 (low $12.71, high $24.20) — a potential gain of +57% on today's $10.77. Momentum favours further upside here.
In 2032, HCM is projected to trade between $12.21 and $23.97, averaging $16.48 — a potential gain of +53% from today's $10.77. That is -3% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
HUTCHMED (China) Limited's 2033 outlook centres on $17.27, within a $12.63 to $25.51 range. That is up +5% on the projected 2032 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2034, HCM could reach as high as $26.84, with a base case around $17.92 and support toward $12.94 — roughly +66% from $10.77. Buyers look set to stay in control over this stretch.
Expect HCM to range from $13.30 to $28.27 through 2035. The $18.63 average target implies a +73% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The HCM price prediction for 2040 points to an average of $25.89 (low $17.52, high $41.48) — a potential gain of +140% on today's $10.77. Buyers look set to stay in control over this stretch.
In 2050, HCM is projected to trade between $32.34 and $90.76, averaging $52.30 — a potential gain of +386% from today's $10.77. That is up +102% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in HCM today (≈ 92.850511 HCM) could be worth
$4,856.33
+$3,856.33 (+386%) by 2050 · US Dollar
Based on the average projected HCM price of $52.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HCMwould be worth at today's price.
$1,000 invested in HCM on Jul 30, 2025 (≈ 54.614966 HCM) would be worth
$588.2
-$411.8 (-41.2%) today · 0.59× · US Dollar
Based on a HCM entry price of $18.31 vs. today's $10.77.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.96 | $982.66 | -1.7% |
| 1 month ago | $10.76 | $1,000.93 | +0.1% |
| 3 months ago | $13.3 | $809.77 | -19.0% |
| 6 months ago | $15 | $718 | -28.2% |
| 1 year ago | $18.31 | $588.2 | -41.2% |
| All time (5.0y) ago | $42.79 | $251.69 | -74.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HCM forecast.
Our base-case forecast reaches $22.00 around 2040.
Implied market cap at $22.00: $3.82B
The multi‑year forecast shows meaningful upside beyond the near term. For 2026, the min is $9.99, the avg is $10.77, the max is $13.42, with an ROI of 0 and neutral sentiment. By 2030, the avg is $14.73, the min $11.23, the max $20.68, with an ROI of 36.7 and a bullish sentiment.
The 2040 projection increases to an avg of $25.89, a min of $17.52, and a max of $41.48, with an ROI of 140.4 and bullish sentiment. By 2050, the avg is $52.30, the min $32.34, and the max $90.76, with an ROI of 385.6 and bullish sentiment. These figures illustrate a strong longer‑term path, but should be treated as estimates rather than guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $14.73, with a min of $11.23 and a max of $20.68, representing an estimated ROI of 36.7 and a bullish sentiment. Note that these are estimates, not guarantees.
The forecast shows neutral sentiment in 2026 and 2027–2029, with a shift to bullish from 2030 onward. The 2030 avg is $14.73 with ROI of 36.7 and the 2050 avg is $52.30 with ROI of 385.6, but these figures are estimates.
Yes, the 2050 forecast has a max of $90.76 and an avg of $52.30, indicating the potential to exceed $50 by 2050. The 2040 max is $41.48, so reaching $50 would be more likely by 2050, with these values representing estimates.
The current price is $10.77. The 30‑day range runs from $9.26 to $12.52.
For 2026, the min is $9.99, the avg is $10.77, the max is $13.42, with an ROI of 0 and sentiment neutral.
HUTCHMED (China) Limited Community Discussion
0Share your HUTCHMED (China) Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.